Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to give consent~* Women of childbearing potential must have a) negative urine pregnancy test b) not be breast feeding c) agree to practice a reliable form of contraception~* Diagnosis of cancer~* Taking at least 60mg oral morphine or equivalent as 24 hour treatment for cancer-related pain~* Experiencing on average 1 - 4 episodes of breakthrough cancer pain per day usually controlled by rescue pain medication~* Able (or via caregiver)to evaluate and record pain relief, assess medication performance at set times after dosing, record adverse events, record each use of the study drug or rescue medication in a diary~* Able to be up and about for 50% of the day or greater~Exclusion Criteria:~* Intolerance to opioids or fentanyl~* rapidly increasing/uncontrolled pain~* pain that is not cancer related

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasalfent, Fentanyl Citrate Nasal Spray (Type: EXPERIMENTAL): None
- Placebo Spray (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).